The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

A grandmother, diagnosed with breast cancer, and her toddler granddaughter, diagnosed with acute myeloid leukemia, are facing ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

The University of Connecticut’s athletic department will host four separate bone marrow registry drives throughout November.

A donut-eating contest helped raise funds for 17-year-old Levi Atkins, who's battling Acute Myeloid Leukemia, while uniting ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

"When you know that your granddaughter, who at that point wasn't even a year old, has already done that treatment, it made me ...

NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Kura Oncology (KURA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from ...

Actinium Pharmaceuticals ( (ATNM) ) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to ...

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...